Tiziana Life Sciences: Surges on patent win for Crohn's disease treatment

Tiziana Life Sciences

18/08/2020 12:16

** U.S.-listed shares of UK-based biotech co  TILST.L 
 TLSA.O  rise 21.5% to $4.9 premarket
    ** U.S. Patent and Trademark Office has granted patent on
methods and use of co's monoclonal antibodies for treatment of
Crohn's disease  urn:newsml:reuters.com:*:nGNE79F55p 
    ** Patent will be published on September 1 - TLSA
    ** Co plans to start mid-stage trial for treatment in Q4 
    ** Up to Monday's close, stock was up nearly four-fold YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3463;))